Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
29 hedge funds and large institutions have $7.09M invested in Bellicum Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 27 closing their positions.
2,193% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $105K
43% less funds holding
Funds holding: 51 → 29 (-22)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
69% less capital invested
Capital invested by funds: $22.6M → $7.09M (-$15.5M)
74% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$203K |
| 2 |
Morgan Stanley
New York
|
+$200K |
| 3 |
Millennium Management
New York
|
+$177K |
| 4 |
SCM
Sio Capital Management
New York
|
+$132K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
-$649K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$516K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$455K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$448K |
| 5 |
Renaissance Technologies
New York
|
-$365K |
BLCM Hedge Fund Activity: Q1 2020 in Review
29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2020, worth a combined $7.09M — down 69% from $22.6M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of BLCM and 7 opened new positions — a net loss of 20 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $203K. The largest seller was Principal Financial Group, exiting entirely with an estimated $649K sold.
- 29 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2020, down from 51 in Q4 2019.
- Funds reported $7.09M of Bellicum Pharmaceuticals, Inc. stock for Q1 2020, down 69% quarter-over-quarter.
- 7 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2020 and 27 closed out, a net change of -20 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2020 was Sabby Management, an estimated $203K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2020 was Principal Financial Group, an estimated $649K sold.
Based on aggregated 13F filings for Q1 2020.